ASCO Annual Meeting

The study follows a successful phase 1b/2 study, data from which were presented at the 2021 ASCO Annual Meeting.

Sivakumar was a researcher on a study presented at the 2021 ASCO Annual Meeting that assessed ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.

A single-dose of the targeted radioligand therapy administered with pembrolizumab led to durable objective responses in patients with mCRPC.

Neal D. Shore, MD, discusses results from the phase 2 ODENZA trial which explored patient preference between darolutamide and enzalutamide in men with metastatic castration-resistant prostate cancer.

In this video, lead author Edmund M. Qiao discusses study results presented during the 2021 ASCO Annual Meeting which showed an association between increased prostate-specific antigen screening and improved outcomes in younger African American patients.

“Patients of African ancestry were actually less likely to receive comprehensive genomic profiling earlier in their treatment course than patients of European ancestry, and…patients of African ancestry [were] less likely to be treated in clinical trials,” says Jessica Lee, MS.

The regimen was associated with an approximately 2.5-year absolute benefit in median radiographic progression-free survival versus standard care.

The phase 3 SWOG S1216 trial compared ADT plus either the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Patients with African ancestry were also less likely to be treated on clinical trials versus patients with European ancestry, the investigators reported.

Adding bone-protecting agents to the treatment of men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer helped to reduce their risk for fracture.

Neeraj Agarwal, MD, discusses results from the phase 3 SWOG S1216 trial, which compared ADT plus the novel agent TAK-700 or bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Darolutamide is FDA-approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer being presented during the 2021 ASCO Annual Meeting.

Neeraj Agarwal, MD, discusses health-related quality of life and patient-reported outcomes from the phase 3 TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

Smruthy Sivakumar, PhD, discusses results from a large-scale analysis of ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.

The treatment was also well tolerated, results from an ongoing phase 1/2a dose escalation study indicate.

Overall survival and progression-free survival data from the phase 3 VISION trial were shared as part of the 2021 ASCO Annual Meeting.

Ahead of the 2021 ASCO Annual Meeting, Michael S. Cookson, MD, co-editor in chief of Urology Times, shared his thoughts on the most pivotal abstracts in genitourinary cancer.

Higher screening frequency was associated with a lower risk of metastatic disease at diagnosis and a reduction in prostate cancer–specific mortality.